ScandiDos AB (SE:SDOS)

:SDOS

SDOS

ScandiDos AB

RESEARCH TOOLSreports

ScandiDos AB (SDOS) Price & Analysis

Compare

0 Followers

SDOS Stock Chart & Stats

kr1.15

kr0.01(0.67%)

At close: Mar 06 4:00 PM EST

kr1.15

kr0.01(0.67%)

Day’s Range― - ―

52-Week Rangekr0.90 - kr1.50

Previous CloseN/A

Volume16.76K

Average Volume (3M)69.69K

Market Cap

kr56.90M

Enterprise Valuekr51.05M

Total Cash (Recent Filing)kr5.85M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.37

Next Earnings

Jun 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding57,011,086

10 Day Avg. Volume66,689

30 Day Avg. Volume69,692

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)1.28

Price to Sales (P/S)0.95

P/FCF Ratio-21.18

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA near-zero debt load provides durable financial flexibility: it lowers insolvency risk, preserves access to capital, and lets management prioritize R&D, service expansion or targeted investment without immediate debt servicing pressures, supporting stability over the next 2–6 months.

Narrowing Losses / Improving MarginsMaterial improvement in net loss indicates better cost control and operational leverage. If sustained, narrowing losses strengthen the path to consistent profitability, reduce future capital needs, and increase the chance the business becomes self-funding within a multi-quarter horizon.

Niche Radiotherapy QA Market With Recurring RevenueA focused product set for radiotherapy QA and recurring service/software revenue create durable, sticky cash flows driven by installed base and clinical regulation. Structural adoption of advanced radiotherapy sustains underlying demand for QA solutions over the medium term.

Bears Say

Recent Revenue DeclineA declining top line reduces operating leverage and strains the company’s ability to cover fixed costs and fund growth initiatives. Continued revenue contraction would impede margin recovery and make achieving sustainable profitability more difficult over the next several quarters.

Negative Operating And Free Cash FlowOngoing cash burn limits strategic optionality and increases reliance on external capital or equity financing. Even with narrower losses, persistent negative cash flow can force resource constraints, delay commercialization efforts, and pressure balance-sheet runway over months.

Small Organizational ScaleA very small workforce constrains sales reach, customer support capacity and R&D throughput versus larger medical-device competitors. Limited scale raises execution risk on international rollouts and prolonged procurement cycles, potentially slowing revenue recovery and market share gains.

SDOS FAQ

What was ScandiDos AB’s price range in the past 12 months?

ScandiDos AB lowest stock price was kr0.90 and its highest was kr1.50 in the past 12 months.

What is ScandiDos AB’s market cap?

ScandiDos AB’s market cap is kr56.90M.

When is ScandiDos AB’s upcoming earnings report date?

ScandiDos AB’s upcoming earnings report date is Jun 24, 2026 which is in 86 days.

How were ScandiDos AB’s earnings last quarter?

ScandiDos AB released its earnings results on Mar 18, 2026. The company reported -kr0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.03.

Is ScandiDos AB overvalued?

According to Wall Street analysts ScandiDos AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ScandiDos AB pay dividends?

ScandiDos AB does not currently pay dividends.

What is ScandiDos AB’s EPS estimate?

ScandiDos AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ScandiDos AB have?

ScandiDos AB has 57,011,086 shares outstanding.

What happened to ScandiDos AB’s price movement after its last earnings report?

ScandiDos AB reported an EPS of -kr0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.99%.

Which hedge fund is a major shareholder of ScandiDos AB?

Currently, no hedge funds are holding shares in SE:SDOS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ScandiDos AB

ScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. The company offers Delta4 Family solution for pre treatment and at treatment dose verification covering various treatment technologies, such as VMAT, IMRT, SBRT, 4D-RT, and TomoTherapy; Delta4 Discover, a transmission detector that provides confidence and patient safety based on real time measurements; and Delta4 Phantom+, a system that offers accurate and verification of IMRT, VMAT, and TomoTherapy plans. It also provides HexaMotion, a motion management solution; Delta4DVH Anatomy, a software that verifies and analyzes the dose delivered in the patient anatomy; and Delta4 Machine QA, a software to perform QA with respect to rotation, start-up behavior, and dynamic beam modulation. The company was founded in 2005 and is headquartered in Uppsala, Sweden.